オランザピン誘発の高血糖症に対するメトホルミンの有効性: オープン・ラベル前向き研究
Kah Kheng Goh1,2,3,4, Tzu-Hua Wu2,5, Chun-Hsin Chen1,2,3
1Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
International journal of psychiatry in clinical practice
|August 28, 2025
まとめ
メトフォーミンはオランザピンを服用した患者でプロラクチン濃度の上昇を効果的に低下させた. この介入は代謝のパラメータも改善し,抗精神病薬による副作用の管理の可能性を示した.
科学分野:
- 内分泌学
- 薬理学について
- 精神科
背景:
- オランザピンなどの抗精神病薬は,一般的にプロラクチン濃度の上昇 (超プロラクチン血症) を引き起こします.
- 患者の健康状態と治療の順守に影響を与える様々な副作用を引き起こす可能性があります.
研究 の 目的:
- オランザピン誘発の高血糖症の管理におけるメトフォーミンの有効性を調査する.
- 統合失調症患者の代謝パラメータに対するメトホルミンの影響を評価する.
主な方法:
- 安定したオランザピン治療を受けた31人の統合失調症患者 (18~60歳) を対象とした前向きな研究.
- メトフォーミン1500mg/日による8週間の介入で,プロラクチンと代謝パラメータをベースラインと2週間の間隔で測定した.
主要な成果:
- メトフォーミンはプロラクチン濃度 (p=0. 005) を著しく低下させ,効果の大きさは中程度であった.
- プロラクチン値の低下は,ベースラインのプロラクチンとグルコース値の上昇と相関する.
- 体重,BMI,インスリンレベル,グルコース,およびインスリン抵抗性の有意な改善が観察されました.
結論:
- メトフォーミンは,オランザピンが誘発した高血糖症を,軽度の上昇の場合でも有効に逆行させました.
- この研究は,抗精神病薬の副作用を軽減する治療法としてメトホルミンの可能性を示唆しています.
- この患者群ではメトフォーミンが代謝健康に有益な効果を示した.
関連する概念動画
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
439
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
593
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
593
Mania and Antimanic Drugs: Overview
318
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
318
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252


